Skip to main content

Table 2 Golimumab and placebo effect estimates

From: Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies

Outcome Fixed effect Value Standard error p value
DAS Baseline 5.931 0.057 0.000
  GOL −1.892 0.054 1.760×10−241
  PBO −0.640 0.058 5.277×10−28
lCRP Baseline 1.246 0.022 0.000
  GOL −0.482 0.024 7.423×10−88
  PBO −0.116 0.024 1.479×10−6
rSJC Baseline 3.752 0.063 0.000
  GOL −1.799 0.059 3.150×10−191
  PBO −0.690 0.065 9.436×10−26
rTJC Baseline 4.992 0.077 0.000
  GOL −1.876 0.068 1.149×10−159
  PBO −0.657 0.074 6.040×10−19
  1. Fixed effect estimates of baseline disease state, GOL effect size, and PBO effect size derived from linear mixed models that used various outcomes (e.g., DAS, lCRP, etc.) as response metric DAS Disease Activity Score, GOL golimumab, lCRP log transform of C-reactive protein metric, PBO placebo, rSJC square root of SJC, rTJC square root of TJC, SJC swollen joint count, TJC tender joint count